Treated XXXX . Histological, immunohistochemical and cell kinetic studies.

@entity1 @entity263 @entity6517 @entity5 @entity4 @entity189 @entity1463 @entity1486
Classification, histological and cytological grading of @entity263 , as well as the exact determination of the @entity5 stage, are the decisive criteria for the therapy to be followed. 163 morphological control examinations were analyzed for a period of 5 years on 97 @entity1 before, under and after hormonal or radiotherapy. 57% of the controlled @entity263 were uniformly glandular, or predominantly glandular, i.e., of pluriform structure, malignity grade Ib/IIa. 41% corresponded to cribriform and solid @entity189 with grade IIa, IIb and III. Under hormonal therapy, the typical epithelial and stromal changes were evident, like coarse vacuolization of cytoplasm, progressive nuclear pyknosis, @entity4 , as well as @entity1463 and @entity6517 . Under radiotherapy, the degree of @entity1463 and nuclear changes was even more evident. Polynuclear, bizarre @entity5 cells predominated. With @entity189 to hormonal or radiotherapy, the immunohistochemical markers ( @entity1486 ) were markedly reduced or missing. @entity189 , up to 5 years after therapy, showed regression grade I in 30.1%, II in 18.3, III in 43.0% and X in 8.6%. In cribriform/solid @entity189 , the regression was less marked. Grade I was observed in 42.9%, grade II in 21.4%, and grade III in 35.7% of the cases. There was no regression grade X. The results have shown that responsiveness of @entity189 to therapy can well be analyzed by use of certain histological and cytological criteria for grading and regressional grading. The experiences so far have shown that concerning radiation, 12-18 months after conclusion of therapy is a favorable moment for posttherapy controls. Under hormonal therapy, the therapy control should be performed 6 months after beginning. The same applies for cytological therapy controls.
